A Chemically Sound Reason to Exercise with HCV
Aug 16, 2011
1 Comment
One of the biochemical consequences of physical activity helps those with Hepatitis C maintain their liver's health.
Continue reading »Research & Treatment News
Share
Follow Us
Two Liver Cancer Discoveries May Impact Hepatitis Patients
Researchers in different countries make two liver cancer discoveries, progress that could have a positive impact on people with advanced chronic Hepatitis B or Hepatitis C.
Continue reading »Surprising Data on What Typically Ends the Fight Against Hep C
Aug 9, 2011
85 Comments
Despite a less than uplifting prognosis for those with chronic Hepatitis C, it is not a death sentence.
Continue reading »French Make Progress with Preventive Hep C Vaccine
In animal subjects, French researchers developing a preventive Hepatitis C vaccine announced success; hopefully human trials will follow.
Continue reading »Even Better Hep C Outcome with Vertex’s Quad Combo
In a trial called Zenith, Vertex finds that a combination of four drugs knocked out Hepatitis C in half of participants in just 12 weeks.
Continue reading »Side Effects of the Two New Hep C Drugs
Just like any drug, the two newly approved medications for Hepatitis C have side effects.
Continue reading »European Union Approves Victrelis for Chronic Hep C
Representing the European Union's first approved Hepatitis C drug in a decade, Victrelis (boceprevir) can now be used in Europe to battle the most persistent strain of this prevalent liver virus.
Continue reading »Liver Fibrosis Reduced with HIV-Hep C Co-Infection
In an Italian study of people co-infected with HIV and Hepatitis C, taking Maraviroc helped reduce liver stiffness.
Continue reading »All Cured of Hep C Genotype 2 or 3 in Arm of PSI-7977 Trial
Jul 22, 2011
1 Comment
In a Phase 2b study with pegylated interferon and ribavirin, Pharmasset's PSI-7977 had a 100 percent success rate against Hepatitis C genotypes 2 and 3.
Continue reading »Financial Help for Old and New Hepatitis C Drugs
Jul 21, 2011
3 Comments
For the estimated 60 million Americans without health insurance, the Hepatitis C drug companies have programs in place to finance the cost of antiviral medications.
Continue reading »
